INTRODUCTION
Multiple sclerosis (MS) is an inflammatory disease of the CNS and a frequent cause of neurological disability. In MS, chronic disability is due to progressive axon degeneration (Trapp and Nave, 2008) . During the initial phase of the disease, axon degeneration predominantly occurs in focal white matter lesions, while in later stages of the disease, a more widespread pattern of axonal pathology emerges (Lassmann et al., 2012) . Such diffuse axon degeneration is reminiscent of the continuous decline observed in classical neurodegenerative diseases, but the mechanisms that cause progressive axon loss in MS remain poorly understood. Axonal transport, which shuttles critical cell body-derived cargos back and forth between soma, axon, and synapses (Coleman, 2005; Millecamps and Julien, 2013) , appears to be a vulnerable target in neuronal homeostasis. Indeed, impairments of axonal transport have been associated with axon degeneration in neurological disease. First, transport disturbances have been described in several neurodegenerative conditions and appear to precede the initiation of overt neurodegeneration (Millecamps and Julien, 2013) . Second, mutations that cause neuronal and axonal degeneration in mice and humans often affect axonal transport (Baloh et al., 2007; Ebbing et al., 2008) and, in converse, mutations that affect transport can cause axon degeneration (Hurd and Saxton, 1996; LaMonte et al., 2002) . Finally, therapeutic strategies that restore transport tracks and reverse transport deficits have been shown to slow the progression of axon degeneration, for example, in models of Charcot-Marie-Tooth disease or hereditary spastic paraplegia (d 'Ydewalle et al., 2011; Denton et al., 2014) .
While transport disturbances have thus been linked to classical neurodegenerative diseases, it is currently unclear whether and when similar transport deficits occur in neuroinflammatory lesions, how such deficits relate to structural axon damage, and which inflammatory mediators can impede transport. Here we use in vivo two-photon imaging to directly measure organelle transport and microtubule dynamics in acute and chronic mouse models of MS. Remarkably, we found that in neuroinflammatory lesions axonal transport was not only reduced in morphologically altered axons, but also in the majority of normal-appearing axons. Further analysis showed that transport impairments are already present before demyelination or major abnormalities of microtubule tracks became apparent. This indicates that transport deficits represent an early and pervasive stage of axonal dysfunction. Transport deficits recovered within days in an acute MS model but failed to resolve in a chronic model, resulting in a lasting impairment of distal organelle supply. Redox scavenging, as well as acute anti-inflammatory interventions, quickly restored transport levels, demonstrating that transport deficits can be therapeutically ameliorated.
RESULTS

Widespread Deficits of Organelle Transport Are Observed in Multiple Sclerosis Models
To investigate how organelle transport is affected by neuroinflammation, we used an acute experimental autoimmune encephalomyelitis (EAE) model of MS, in which inflammatory lesions with axon damage evolve in the spinal cord of mice (Figures 1A and 1B) . We then established a spinal in vivo two-photon imaging approach (Davalos et al., 2008; Niki c et al., 2011 ) that allowed us to follow the dynamics of individual fluorescently labeled organelle cargos, such as mitochondria (in Thy1-MitoCFP mice; Misgeld et al., 2007) or peroxisomes (in newly generated Thy1-PeroxiYFP mice), in individual spinal axons in the healthy and inflamed spinal cord ( Figures 1C and 1D and Movies S1 and S2 available online). Neuroinflammatory lesions were identified in vivo by application of a nuclear dye that reveals cellular infiltration (Romanelli et al., 2013) or based on the local presence of damaged axons (see Supplemental Experimental Procedures). Our in vivo recordings showed that anterograde and retrograde transport of mitochondria and peroxisomes were markedly reduced in spinal axons that pass through these lesions ( Figures  1E and 1F and Movie S1). Strikingly, transport was not only reduced in axons that were swollen and hence had entered the degeneration process (Niki c et al., 2011) , but also in the majority of normal-appearing axons in the lesion area. In contrast, dorsal root axons imaged proximal to the lesion area displayed normal anterograde transport and even increased retrograde transport rates ( Figure S1 ). In inflammatory lesions, such localized transport deficits were not only observed acutely but persisted for several weeks in a chronic EAE model ( Figure S2A ). These transport deficits resulted in a long-lasting reduction of net organelle delivery from the soma toward the synapses, as anterograde transport rates were more profoundly affected than retrograde ones. In the case of mitochondria, for example, parts of axons that are distal to inflamed sites lacked the supply of several hundred mitochondria per day ( Figure S2B ). Indeed, anterograde tracing of dorsal root ganglion (DRG) axons that pass through the inflamed spinal cord revealed that local axon collaterals within the lumbar gray matter, as well as the distal axon compartments in ascending tracts of the dorsal thoracic spinal cord, became depleted of mitochondria in a chronic (but not in an acute) EAE model ( Figure S3 ). 
Neuron
Transport Deficits in MS Models
To better understand why organelle transport is impaired, we tracked the movements of individual mitochondria through acute neuroinflammatory lesions in normal-appearing axons. Our results show that while parameters such as moving speed and stop frequency were only moderately altered, the duration of mitochondrial stops was dramatically increased for both anterogradely and retrogradely moving mitochondria in neuroinflammatory lesions. Furthermore, persistent arrests of organelles were almost exclusively observed in the inflamed spinal cord (Figure 2 ). Such persistent stops likely explain the increased density of organelles (mitochondrial density: 0.15 ± 0.003 mitochondria/mm and 10-35 axons per group). Indeed, such organelle accumulations have also been previously documented in MS tissue (Vergo et al., 2011; Witte et al., 2009 ).
Transport Deficits Precede Structural Alterations of Axons, Cargos, or Microtubule Tracks
We next asked whether focal structural alterations could explain why organelles accumulate in neuroinflammatory lesions. Demyelination or dysmyelination, for instance, have been previously shown to associate with increased organelle density in axons (Edgar et al., 2004; KiryuSeo et al., 2010; Ohno et al., 2014) . To address the role of demyelination in vivo, we labeled myelin in the intact spinal cord using a vital dye (Romanelli et al., 2013) and measured organelle transport in acute neuroinflammatory lesions. Interestingly, transport deficits were already present in myelinated axons (Figures S4A and S4B) and were thus not secondary to demyelination.
Another possibility would be that damage to mitochondria themselves, as described in neuroinflammatory lesions (Niki c et al., 2011; Witte et al., 2014) , might lead to transport disruption. However, when we measured mitochondrial transport rates in intact-appearing axons with either normally shaped or morphologically altered mitochondria, we found that transport deficits preceded structural changes to organelles ( Figures  S4C and S4D) .
Finally, we asked whether alterations of the microtubule tracks, along which organelles travel, interfere with transport. To assess the state of microtubules in individual axons at different stages of neuroinflammatory damage, we analyzed the orientation of microtubule tracks by electron microscopy ( Figures 3A-3C ). In addition, we evaluated the presence of posttranslational modifications of tubulin, such as acetylation and tyrosination, which respectively indicate the stabilization or destabilization of microtubules (Janke, 2014) , by quantitative immunohistochemistry ( Figure S5 ). Finally, we directly assayed the density and orientation of dynamic microtubules by in vivo two-photon imaging of Thy1-EB3-YFP mice (Kleele et al., 2014) , which express a fluorescently tagged version of the plus-end binding protein EB3 in neurons ( Figures 3D-3F and Movie S3). Together, these analyses showed that transport deficits occurred in axons before marked alterations of the microtubule cytoskeleton. While there is a subset of normal appearing EAE axons, which show increased microtubule tyrosination, acetylation levels in EAE and control axons are similar, with even a slight increase seen in normal-appearing axons in EAE lesions compared to controls. Furthermore, the orientation of microtubules in electron micrographs, as well as the density and orientation of dynamic microtubule comets, are comparable between control and normal-appearing axons in EAE. In contrast, we found disorganized, tyrosinated, and highly dynamic microtubules in a subset of swollen axons in neuroinflammatory lesions ( Figures 3C-3E , Figure S5 , and Movie S3). Such a destabilization of the microtubule cytoskeleton, which is reminiscent of microtubule changes induced after traumatic axon injury (Erez et al., 2007; Kleele et al., 2014) , might mark the transition to more permanent structural axon damage and predispose affected axons to subsequent degeneration.
Anti-Inflammatory and Anti-Oxidative Interventions Reverse Transport Deficits in Multiple Sclerosis Models
Our results show that transport deficits can be initiated in morphologically normal axons with intact myelin, normal-appearing (F) Quantification of both comet density and mitochondrial flux per axon are plotted derived from recordings in double-transgenic mice with differentially labeled mitochondria and dynamic microtubule ends. Individual axons are indicated by circles with the mean of each group ±SEM indicated by a square. A clear shift to the left within the EAE population indicates a decrease in organelle flux, while no change in comet density is apparent. Dotted gray line indicates 3 SDs from the mean comet density in control mice showing that all stage 0 axons fall within the normal distribution and do not significantly differ from control (n = 33 axons per group from 4 control and 3 EAE mice). Scale bars represent1 mm in (C), top (also for panels in A and B); 100 nm in blow-up in (C) (also for magnified details in A and B); 5 mm in (D), right (also for middle and left). Graph in (E) shows mean + SEM; graph in (F) shows mean ± SEM for values indicated by square symbol; *p < 0.05. cargos, and unaltered microtubule tracks. Hence, transport deficits appear to represent an early state of inflammation-induced axonal ''dysfunction'' rather than a later sequel of structural alterations. This suggests that transport deficits could reverse once the underlying inflammatory driving force subsides. Indeed, transport deficits started to recover within a few days after the peak of EAE in the acute model. This recovery could be accelerated by treating mice at the peak of their symptoms with a single dose of corticosteroids, an intervention that is commonly used to curb disease exacerbation in MS patients (Sellebjerg et al., 2005 ; Figure 4A ). Next, we asked which inflammatory mediators could cause such reversible axonal dysfunction. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) were previously shown to induce transport deficits in vitro (Stagi et al., 2005) and to initiate structural axon damage in vivo (Niki c et al., 2011) . To follow the evolution of transport deficits over time after application of such reactive species, we repetitively measured axonal transport in individual spinal axons of healthy Thy1-MitoCFP mice for several hours. When we applied the NO donor, Spermine NONOate, at a dose that did not induce axonal degeneration, to the exposed spinal cord, organelle transport came to a complete halt within 90 min but could be restarted by application of the NO scavenger cPTIO ( Figure 4B and Movie S4). To determine whether reactive species also contribute to the induction of transport deficits in neuroinflammatory lesions, we treated EAE mice with ROS/RNS scavengers. Indeed, therapeutic neutralization of reactive species not only limits structural axon damage, as we have previously shown (Niki c et al., 2011) , but also ameliorated axonal transport deficits ( Figure 4C ).
DISCUSSION
By assaying the movement of individual axonal organelles in the spinal cord of living mice, we reveal widespread axonal transport deficits in neuroinflammatory lesions. Transport deficits affected diverse organelles such as mitochondria and peroxisomes and both anterograde and retrograde transport. A number of surprising findings emerged from of our study. First, transport deficits were already observed in normal-appearing and myelinated axons, indicating that demyelination is not required for initiation of inflammation-associated transport deficits. At the same time, in line with previous studies (KiryuSeo et al., 2010; Ohno et al., 2014) , we find that demyelination modulates important aspects of axonal transport including the moving speed of anterograde organelle movement (0.31 ± 0.03 mm/s in normal appearing myelinated axons versus 0.49 ± 0.03 mm/s in all normal appearing axons in EAE, n = 17-81 mitochondria from 4-18 Thy1-YFP-16 3 Thy1-MitoCFP-P mice per group), as well as the density of stationary mitochondria (93% ± 6% of control in normal appearing myelinated axons versus 149% ± 5% of control in all normal appearing axons in EAE, n = 30-128 axons from 4-18 Thy1-YFP-16 3 Thy1-MitoCFP-P mice per group). It is thus likely that in neuroinflammatory lesions the final transport pattern reflects both the influences of inflammation and demyelination, the relative importance of which might shift as the disease advances. Second, transport deficits occurred before marked alterations of the ultrastructure or acetylation of microtubule tracks could be observed. Imaging of fluorescently labeled microtubule endbinding proteins further showed that the stability of microtubules was likewise unaltered in the initial stage of axonal dysfunction when transport deficits start to manifest. Third, transport deficits were strikingly reversible, both spontaneously and after intervention, suggesting that altered transport might be a suitable therapeutic target. Indeed, both a standard anti-inflammatory treatment, as well as a redox-scavenging protocol, efficiently reversed the transport deficit.
So how does inflammation cause reversible transport deficits? While multiple factors are likely to contribute, a number of observations point to alterations of motor engagement at the microtubules. First, we did not find any structural changes of axons, cargos, or tracks that correlated with transport deficits, making it unlikely that overt structural damage disrupts transport. Second, both mitochondria and peroxisomes, as well as anterograde and retrograde transport, are affected, making a primary interruption of organelle-specific linkers, such as Miro or Trak (Schwarz, 2013) , or of specific motors, such as kinesins or dynein, unlikely. Finally, tracking of single organelles revealed that stop duration is dramatically increased in the inflamed spinal cord, suggesting a temporary disengagement of cargos from tracks. This notion is further supported by the increased density and content of mitochondria observed in EAE axons that suggest that moving mitochondria accumulate in the lesion area. Indeed, arrest of moving mitochondria (which are comparatively smaller than resting ones; Misgeld et al., 2007 and data not shown) might explain the drop in the average mitochondrial volume observed in early stages of axon damage, but which later normalizes as axon damage progresses, perhaps due to mitochondrial fusion or local growth (relative mitochondrial volume: 63% ± 1% in normal appearing axons and 97% ± 4% in swollen axons in EAE, n = 397-1,361 mitochondria from 3-4 Thy1-YFP-16 3 Thy1-MitoCFP-S mice per group). The organelle accumulations we found could thus be caused by local molecular alterations of microtubules that affect binding of different motor-cargo complexes. Indeed, the reduced severity and faster recovery of retrograde transport deficits we observed could be explained by the fact that dynein motors can circumvent such obstacles more efficiently than kinesins (Dixit et al., 2008) . While we observe a more prominent impairment of the anterograde transport, it should be noted that in other neurological conditions, e.g., in a mouse model of hereditary spastic paraplegia, a selective accumulation of retrograde motor proteins and consequent disturbance of retrograde transport have been described (Edgar et al., 2004) . Obstacles for organelle transport could in principle result from posttranslational modification and destabilization of microtubules, e.g., by tyrosination or deacetylation (Dunn et al., 2008; Reed et al., 2006) . Our results, however, show no evidence for microtubule deacetylation and indicate that microtubule tyrosination as well as changes in microtubule dynamics primarily occur in the late stages of axon damage ( Figures 3C-3E and Figure S5 ). An alternative cause for motor-to-track disruptions is the excessive attachment of microtubule-associated proteins (MAPs), which can competitively inhibit the binding of motors to microtubules (Dixit et al., 2008) . Notably, MAPs can be targeted by reactive oxygen or nitrogen species either directly (Stroissnigg et al., 2007) or through activation of upstream kinases (Dias-Santagata et al., 2007) . The quick reversal of NO donor-induced transport deficits that occurred after application of the NO scavenger cPTIO ( Figure 4B ) is compatible with the idea that reversible MAP modifications such as oxidation or phosphorylation mediate transport arrest.
Taken together, our data thus suggest that reactive species released by activated immune cells in neuroinflammatory lesions acutely induce transport disruptions by altering the attachment of motor/cargo complexes to microtubules. Notably, these transport deficits could be induced by NO donor doses that were lower than those that cause structural axon damage (Niki c et al., 2011) . This dose dependence of structural versus functional axon impairments suggests that in an inflammatory lesion, there is a center where high doses of reactive species induce structural axon damage, surrounded by a larger ''penumbra,'' in which lower doses of such mediators cause transient axonal dysfunction. Consequently, when inflammation subsides, for example during remission of an acute neuroinflammatory lesion, transport recovers within days in the penumbral zone. The localized nature of the transport deficits we observe is underlined by our findings that within dorsal root axons that reside outside the CNS and are therefore not locally exposed to inflammation, anterograde flux is normal, while retrograde flux is significantly increased compared to control ( Figure S1 ). The latter indicates that some cargoes reverse when confronted with a structural or functional barrier, similar to what occurs following traumatic axon transection (Misgeld et al., 2007) . While transport deficits are thus locally induced, they likely also affect organelle flux in axons both proximal and distal to the lesion area, which could further affect the transport rates measured in those axons that pass through several lesions. Still, when short-lasting, such transport deficits probably have no immediate detrimental consequences for affected axons ( Figures  S3C and S3D ) and even structurally affected axons can recover during remission (Niki c et al., 2011) . However, in situations in which inflammation persists, even at low levels, as in progressive MS and its models, transport deficits are perpetuated. As anterograde transport is predominantly affected, this limits the provision of vital organelles and ultimately results in ''starvation'' of distal axonal arbors ( Figure S3 ). Ensuing axonal dystrophy would probably first manifest most distally at the synapse and follow a ''dying-back'' pattern (Coleman, 2005) . Indeed, recent histopathological studies provide evidence for prominent synaptic pathology in progressive MS patients (Dutta et al., 2011; Mori et al., 2013) . Preventing persistent transport deficits, e.g., by prolonged redox scavenging, might thus help to reverse transport-based axon dysfunction and thereby help to counteract emerging axonal dystrophy.
EXPERIMENTAL PROCEDURES Transgenic Animals
In Thy1-YFP-16 (Jackson Laboratory strain designation: Tg(Thy1-YFP) 16Jrs/J), Thy1-OFP-3, and Thy1-CFP-5) mice, a large proportion of axons is labeled, while the Thy1-GFP-S line labels only a small subset (Brill et al., 2011; Feng et al., 2000) . In Thy1-MitoCFP-P and Thy1-MitoCFP-S (Jackson Laboratory strain designation: Tg(Thy1-CFP/COX8A)S2Lich/J) mice, a mitochondrial import sequence directs CFP expression selectively to neuronal mitochondria (Misgeld et al., 2007) . To study mitochondria transport rates in the acute EAE model, we used double-transgenic Thy1-YFP-16 3 Thy1-MitoCFP-P mice. To study mitochondrial transport in chronic EAE, we obtained BiozziABH mice from Harlan Laboratories (strain designation BiozziABH/RijHsd) and crossed them with Thy1-MitoCFP-P or Thy1-MitoCFP-S mice. F1 mice were used for analysis. Thy1-YFP-EB3-J045 mice, which express a YFP-tagged version of the plus-end binding protein EB3 selectively in neurons (Kleele et al., 2014) were used for in vivo microtubule ''comet'' analysis and crossed with Thy1-OFP-3 mice to visualize axons or Thy1-MitoCFP-P for concomitant imaging of mitochondria.
See details of the generation of peroxisome mice, in vivo microscopy and analysis, tissue preparation and analysis, surgical procedures, and virus production in Supplemental Experimental Procedures.
Statistical Analysis
All data sets were tested for normal distribution with the D'Agostino-Pearson normality test using GraphPad Prism software. If the data sets failed said test, a nonparametric test was chosen to compare the significance of means between groups (Mann-Whitney test for two samples, Kruskal-Wallis test followed by Dunn's Multiple Comparison test for more than two samples). The chosen statistical test is indicated in each accompanying figure legend along with its corresponding p value if applicable. 
